Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBrief Communications

Accurate Dose Calibrator Activity Measurement of 90Y-Ibritumomab Tiuxetan

Jeffry A. Siegel, Brian E. Zimmerman, Kory Kodimer, Mary A. Dell and William E. Simon
Journal of Nuclear Medicine March 2004, 45 (3) 450-454;
Jeffry A. Siegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian E. Zimmerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kory Kodimer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary A. Dell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Simon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Correction factor (CF) as function of volume normalized to 6 mL, determined by site 1 based on measurements obtained on 1 CRC dose calibrator. Volume dependence is 0.28%/mL.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Correction factor (CF) as function of volume normalized to 6 mL, determined by site 2 based on measurements obtained on 3 CRC (•) and 1 Atomlab (♦) dose calibrators. Volume dependence is 0.21%/mL and 0.16%/mL, respectively.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Correction factor (CF) as function of volume normalized to 6 mL, determined by site 3 based on average of measurements obtained on 3 CRC dose calibrators. Bold line (♦) represents results for sequential 1-mL volume withdrawal from 9 to 3 mL, and dashed line (•) represents results for sequential 1-mL volume addition from 3 to 9 mL. Volume dependence is 0.20%/mL and 0.11%/mL, respectively.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Correction factor (CF) as function of volume normalized to 6 mL, determined by sites 4 (•) and 5 (▪) based on average of measurements obtained on 3 Mark V and 15 Atomlab dose calibrators, respectively. Volume dependence is 0.12%/mL and 0.13%/mL, respectively.

Tables

  • Figures
    • View popup
    TABLE 1

    Dose Calibrators Used and 90Y Activity Measurement Procedures at Each Site

    SiteCalibrator90Y Activity measurementProcedure
    15 CRC-15R90Y in saline*Calibrated dial setting determination: Start activity and volume of 1,406 MBq (38 mCi) in 3 mL Volume dependence: Start activity and volume of 81.4 MBq (2.2 mCi) in 3 mL Sequential addition of 1 mL saline up to 9 mL
    2CRC-12, CRC-15R, 35R, and Atomlab 10090Y in salineA. Start activity and volume of 1,184 MBq (32 mCi) in 8 mL B. Dilute with YCl3/HCl carrier to give enough volume for preparation of syringes and liquid scintillation master C. Accurately (to within 0.1%) dispense large volume master into syringes whose needles had been previously sealed to prevent leaks—total of 14 syringes prepared over the volume range, with several repeated preparations at 3, 5, 7, and 9 mL to study syringe variability and repeatability D. Prepare nominally 200-fold dilution of large volume master for liquid scintillation measurements E. Determine activity concentration of diluted solution and master by liquid scintillation counting using 2 different, independent techniques
    90Y ibritumomab tiuxetan in formulation bufferSame procedure as for 90Y in saline, but large volume master is prepared with formulation buffer instead of carrier; smaller number of syringes are prepared (3, 5 [×2], 7 mL); liquid scintillation cocktails are prepared using both formulation buffer and carrier solution to study composition/stability effects
    33 CRC-15R90Y ibritumomab tiuxetan in formulation bufferStart activity and volume of 1,184 MBq (32 mCi) in 9 mL Sequential withdrawal of 1 mL of solution volume down to 3 mL Sequential addition of 1 mL ibritumomab tiuxetan in formulation buffer up to 9 mL
    43 Mark V90Y in salineStart activity and volume of 509 MBq (13.8 mCi) in 3 mL Sequential addition of 1 mL saline up to 9 mL
    515 Atomlab†90Y in saline‡Start activity and volume of 481 MBq (13.0 mCi) in 3 mL Sequential addition of 1 mL saline up to 9 mL
    • ↵* Activity for calibrated dial setting determination and volume dependence study are different because of use of different syringes.

    • ↵† Ten new and 5 repaired units as old as 11 y; all 4 models of this type of dose calibrator use the same chamber assembly, so there is no need to distinguish between models.

    • ↵‡ During initial volume test, on the 8 mL step, a backfill into the saline vial resulted in source material loss, but initial calibration for activity measurement was unaffected. Volume test was repeated, with a start activity of 92.5 MBq (2.5 mCi) in 3 mL. Repeated results are reported; no backfill was detected.

    • View popup
    TABLE 2

    Calibrated Dial Setting for Each Dose Calibrator at Each Site

    SiteCalibratorSetting
    15 CRC48, 47, 50, 52, 53
    23 CRC58 ± 2*, 55 ± 2*, 54 ± 2*
    Atomlab393 ± 6*
    33 CRC47, 48, 47
    43 Mark V897, 897, 896
    510 New Atomlab375, 375, 374, 375, 378, 372, 374, 376, 375, 373
    5 older units after recalibration394, 373, 363, 368, 371
    SummaryAtomlabmean calibrated dial setting = 375; range = 363–394
    CRCmean calibrated dial setting = 51; range = 47–60
    Mark Vmean calibrated dial setting = 897; range = 896–897
    • ↵* Uncertainties on the dial settings are expanded uncertainties determined from the combined standard uncertainty on the 90Y activity calibration. The uncertainties at the other sites were not evaluated; thus, only ranges of values are given.

    • For the CRC dose calibrators, all dial settings are ×10; that is, the instrument readout must be multiplied by a factor of 10 to obtain the correct activity value. For the Mark V dose calibrators, all dial settings are ×100.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 45 (3)
Journal of Nuclear Medicine
Vol. 45, Issue 3
March 1, 2004
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Accurate Dose Calibrator Activity Measurement of 90Y-Ibritumomab Tiuxetan
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Accurate Dose Calibrator Activity Measurement of 90Y-Ibritumomab Tiuxetan
Jeffry A. Siegel, Brian E. Zimmerman, Kory Kodimer, Mary A. Dell, William E. Simon
Journal of Nuclear Medicine Mar 2004, 45 (3) 450-454;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Accurate Dose Calibrator Activity Measurement of 90Y-Ibritumomab Tiuxetan
Jeffry A. Siegel, Brian E. Zimmerman, Kory Kodimer, Mary A. Dell, William E. Simon
Journal of Nuclear Medicine Mar 2004, 45 (3) 450-454;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody
  • Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
  • Google Scholar

More in this TOC Section

  • Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
  • Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
  • Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with (R)‐11C-Verapamil PET
Show more Brief Communications

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire